EUVIMEDEUVIMED entdecken
Crossref

DAB2IP modulates intestinal inflammation by enhancing ILC3 function in the gut

Liang Liu, Benjamin Davidorf, Peixian Dong, John Yu, David Ho, Bing Zhang, Zhiheng He iD

The Journal of Immunology · 15.04.2026 · 215 (4)

DOI: 10.1093/jimmun/vkag050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 19.04.2026. Verfasst von Liang Liu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Immune Therapeutics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States. Hauptthemen laut MEDLINE: Intestinal Mucosa, Lymphocytes, ras GTPase-Activating Proteins, Colitis. Die Arbeit nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Group 3 innate lymphoid cells (ILC3s) preserve intestinal barrier integrity by producing IL-22 and IL-17A, yet the molecular mechanisms that maintain these cytokines during inflammation are incompletely defined. Here, we identify DAB2IP as a cell-intrinsic regulator of ILC3 effector function. In human inflammatory bowel disease mucosa, DAB2IP expression is reduced and associated with transcriptional programs linked to impaired epithelial repair. In murine models, inflammatory cues dynamically modulate Dab2ip in ILC3s, and genetic loss of DAB2IP diminishes IL-22 and IL-17A, compromising host defense during Citrobacter rodentium infection, and exacerbates dextran sulfate sodium–induced colitis. Mechanistically, DAB2IP enables efficient NF-κB activation, promoting IκBα degradation, p65 nuclear accumulation, and thus transcription of Il22/Il17a and NF-κB targets. These results reveal a context-dependent role for DAB2IP as a positive regulator of NF-κB in ILC3s, highlighting its previously unknown function in mucosal immunity and epithelial repair, and suggesting that restoring DAB2IP signaling could enhance barrier protection during intestinal inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Intestinal MucosaLymphocytesras GTPase-Activating ProteinsColitisEnterobacteriaceae InfectionsInflammatory Bowel DiseasesAnimalsMiceHumansImmunity, InnateNF-kappa BCitrobacter rodentiumInterleukin-22Mice, Inbred C57BLInterleukinsMice, KnockoutIntestinal Barrier FunctionInterleukin-17Signal TransductionDisease Models, Animal

Stichwörter der Autor:innen

DAB2IPcytokine productioninnate immunityinnate lymphoid cells 3 (ILC3)mucosal immunity

Substanzen

ras GTPase-Activating ProteinsNF-kappa BInterleukin-22DAB2IP protein, humanInterleukinsInterleukin-17

Autor:innen und Institutionen

  • Department of Immunology and Immune Therapeutics, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
  • Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.
  • Department of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States.

ORCID-Profile: Zhiheng He

Zitieren

APA

Liu, L., Davidorf, B., Dong, P., Yu, J., Ho, D., Zhang, B., & He, Z. (2026). DAB2IP modulates intestinal inflammation by enhancing ILC3 function in the gut. The Journal of Immunology, 215(4). https://doi.org/10.1093/jimmun/vkag050

Vancouver

Liu L, Davidorf B, Dong P, Yu J, Ho D, Zhang B, et al. DAB2IP modulates intestinal inflammation by enhancing ILC3 function in the gut. The Journal of Immunology. 2026;215(4). doi:10.1093/jimmun/vkag050

BibTeX
@article{Liu2026,
  author = {Liu, Liang and Davidorf, Benjamin and Dong, Peixian and Yu, John and Ho, David and Zhang, Bing and He, Zhiheng},
  title = {DAB2IP modulates intestinal inflammation by enhancing ILC3 function in the gut},
  journal = {The Journal of Immunology},
  year = {2026},
  volume = {215},
  number = {4},
  doi = {10.1093/jimmun/vkag050}
}
Kostenlos starten →